Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Sae Yumita"'
Autor:
Takayuki Kondo, Kentaro Fujimoto, Kisako Fujiwara, Sae Yumita, Takamasa Ishino, Keita Ogawa, Miyuki Nakagawa, Terunao Iwanaga, Keisuke Koroki, Hiroaki Kanzaki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Sadahisa Ogasawara, Shingo Nakamoto, Tetsuhiro Chiba, Jun Kato, Keiichi Fujiwara, Naoya Kato
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract The pathogenesis of acute liver failure (ALF) involves cell death. Necroptosis is a newly suggested programmed cell death, and receptor-interacting protein kinase 3 (RIPK3) has been reported as a marker for necroptosis. However, there are fe
Externí odkaz:
https://doaj.org/article/3e4e126c68c14363a57501f3cba46624
Autor:
Masanori Inoue, Sadahisa Ogasawara, Kazufumi Kobayashi, Tomomi Okubo, Norio Itokawa, Masamichi Obu, Kentaro Fujimoto, Hidemi Unozawa, Sae Yumita, Kisako Fujiwara, Miyuki Nakagawa, Hiroaki Kanzaki, Keisuke Koroki, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Shingo Nakamoto, Kengo Nagashima, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Naoya Kato
Publikováno v:
Liver Cancer, Pp 1-1 (2024)
Introduction: Macrovascular invasion (MVI) is a strong prognostic factor for advanced hepatocellular carcinoma (HCC). The current criteria for radiological assessment are unclear in evaluating the impact of MVI on systemic therapy. In this study, we
Externí odkaz:
https://doaj.org/article/c53294c0a6fc47be8eb613a0ebe4f0a7
Autor:
Hiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, Norio Itokawa, Ryohei Yoshino, Kentaro Fujimoto, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Terunao Iwanaga, Miyuki Nakagawa, Kisako Fujiwara, Ryuta Kojima, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Ei Itobayashi, Masanori Atsukawa, Jun Kato, Naoya Kato
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 4, Pp 513-520 (2023)
Abstract Background Cabozantinib was found to be effective as a second- or third-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) in the phase 3 CELESTIAL trial. So far, as immunotherapy has substituted molecula
Externí odkaz:
https://doaj.org/article/48e468f6fb3749d39b8be35352b06933
Autor:
Takayuki Kondo, Kisako Fujiwara, Miyuki Nakagawa, Kentaro Fujimoto, Sae Yumita, Takamasa Ishino, Keita Ogawa, Terunao Iwanaga, Keisuke Koroki, Hiroaki Kanzaki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Sadahisa Ogasawara, Shingo Nakamoto, Tetsuhiro Chiba, Jun Kato, Naoya Kato
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract The effect of the combination of atezolizumab and bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC) on pulmonary arterial hypertension (PAH) is unknown. Estimation of PAH by using computed tomography (CT) has recently been proposed.
Externí odkaz:
https://doaj.org/article/de4d5e3fc7164a0cb2c301cc50e1d96f
Autor:
Sae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, Tadayoshi Kogure, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hideaki Mizumoto, Jun Kato, Naoya Kato
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is t
Externí odkaz:
https://doaj.org/article/e6438030eab2449d8f1c4414595c6e53
Autor:
Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Masanori Inoue, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Yoshihiro Koma, Ryosaku Azemoto, Jun Kato, Naoya Kato
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Purpose Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial. Ramucirumab is used in
Externí odkaz:
https://doaj.org/article/ec4cc9154a2f40df8dcaa61493fe4d89
Autor:
Masato Nakamura, Takayuki Kondo, Yohei Kawasaki, Hideki Hanaoka, Naoya Kato, Sadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima, Masaru Wakatsuki, Asahi Takahashi, Sae Yumita, Miyuki Nakagawa, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Naoya Kanogawa, Tomoko Saito, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Yoshihito Ozawa, Tomoya Kurokawa, Hiroshi Tsuji
Publikováno v:
BMJ Open, Vol 12, Iss 4 (2022)
Introduction Advanced hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) has the worst prognosis among all phenotypes. This trial aims to evaluate whether treatment with durvalumab, alone or in combination with tremelimumab, plus partic
Externí odkaz:
https://doaj.org/article/10cba6c799024b70a6436dd19587d4d4
Autor:
KEITA OGAWA, TETSUHIRO CHIBA, MASATO NAKAMURA, JUN ARAI, JIAQI ZHANG, YAOJIA MA, NA QIANG, JUNJIE AO, SAE YUMITA, TAKAMASA ISHINO, MOTOYASU KAN, TERUNAO IWANAGA, MIYUKI NAKAGAWA, KISAKO FUJIWARA, TAKAFUMI SAKUMA, HIROAKI KANZAKI, KEISUKE KOROKI, YUKO KUSAKABE, KAZUFUMI KOBAYASHI, NAOYA KANOGAWA, SOICHIRO KIYONO, TAKAYUKI KONDO, RYO NAKAGAWA, SADAHISA OGASAWARA, RYOSUKE MUROYAMA, SHINGO NAKAMOTO, TATSUO KANDA, HITOSHI MARUYAMA, JUN KATO, SHOJI MATSUMOTO, TAKAYOSHI ARAI, SHINICHIRO MOTOHASHI, NAOYA KATO
Publikováno v:
Anticancer Research. 43:1043-1052
Autor:
Terunao Iwanaga, Tetsuhiro Chiba, Masato Nakamura, Tatsuya Kaneko, Junjie Ao, Na Qiang, Yaojia Ma, Jiaqi Zhang, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Motoyasu Kan, Miyuki Nakagawa, Kisako Fujiwara, Naoto Fujita, Takafumi Sakuma, Hiroaki Kanzaki, Keisuke Koroki, Yuko Kusakabe, Masanori Inoue, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Takayuki Kondo, Ryo Nakagawa, Sadahisa Ogasawara, Shingo Nakamoto, Ryosuke Muroyama, Jun Kato, Tatsuo Kanda, Hitoshi Maruyama, Naoya Mimura, Takuya Honda, Toshihiko Murayama, Hiroyuki Nakamura, Naoya Kato
Publikováno v:
Biochemical and Biophysical Research Communications. 642:192-200
Transforming growth factor (TGF)-β/Smad pathway is implicated in the pathogenesis of liver fibrosis, a condition characterized by excessive deposition of extracellular matrix (ECM) proteins such as collagen in response to chronic inflammation. It ha
Autor:
Miyuki Nakagawa, Masanori Inoue, Sadahisa Ogasawara, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, Yasuharu Kikuchi, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Takashi Taida, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hideaki Mizumoto, Masami Shinozaki, Jun Kato, Naoya Kato
Publikováno v:
Cancer. 129:590-599
Although the efficacy of atezolizumab has been demonstrated in randomized controlled trials, its long-term efficacy and association with adverse events in real-world practice are unknown. This study was designed to shed light on these issues.In this